ASXL1 and glycogen storage disease VI: Regarding to the prevalence of specific CHIP genes, Wang et al. [17] identified 12.4% of STEMI patients carrying mutations of DNMT3 A or TET2 with a VAF > 2% and Böhme et al. [7] detected 29% of patients of advanced AMI with multivessel diseases and cardiogenic shock having mutations of DNMT3 A, TET2, ASXL1, and JAK2 with a VAF > 2%.